MCR 86.7%, includes $860M of favorable prior-period development

A broad, clean beat, adjusted EPS $6.38 vs $4.08 a year ago, across every segment, but the margin story still leans partly on a one-time reserve tailwind flagged as fading. The one payer in the set actually rewarded by the market this quarter.

“Our reported medical care ratio of 86.7% includes $860 million of net favorable prior period medical development, the majority of which is in-year development.”

Wayne DeVeydt, CFO, UnitedHealth Group

Watch: Q3 MCR holding without further reserve support, and whether more state Medicaid exits follow Louisiana.

MBR 87.4%, down from 89.9% a year ago

Two consecutive quarters of real MBR improvement now, tightened guidance signals management trusts it. The $500M MBR benefit is prior-year estimate changes, including risk adjustment and favorable development, not a simple reserve release. Caremark is the one soft spot, real 340B pressure and value pulled forward from H2.

“Second quarter results reflect pressure in our 340B business and a pull-forward of value previously expected to occur in the second half.”

Brian O. Newman, CFO, CVS Health

Watch: Whether 340B pressure deepens or stabilizes, and 2027 AEP bid behavior on the remaining 25% of Aetna's book.

Benefit expense ratio 89.7%, up 80 bps year over year

A clean beat, adjusted EPS $7.45 versus roughly $6.21 expected, that the market ignored, most analyst attention focused on Medicaid sustainability and confirmed state exits rather than the headline number. The beat included a $0.80 per-share below-the-line benefit management plans to redeploy into one-time H2 investment. Its Medicare Advantage margin target actually held this quarter, the overall enrollment decline traces to commercial, ACA, and Medicaid, not a deliberate MA pullback.

A widely cited CEO quote about this result could not be independently confirmed against the primary transcript in time for this draft, pull the transcript directly before using any direct quote from this call externally.

Watch: Further state-level Medicaid exits beyond D.C. over the next 12 to 18 months.

HBR 89.6%, down from 93.0% a year ago

A real but concentrated beat, about $0.50 of EPS comes from one-time settlements management says will not repeat, layered over Medicaid membership shrinking faster than guided.

“The $0.50 will be a reconciling item when we provide a bridge from 2026 to 2027.”

Drew Asher, EVP and CFO, Centene

Watch: Whether Medicaid attrition holds at 8-9%, or widens further.

Insurance segment benefit ratio 91.2%, exactly in line with guide

Beat both EPS lines and hit its benefit ratio guide exactly, but shares fell as GAAP EPS guidance was cut a second consecutive quarter, now $6.52 versus $8.36 in April and $8.89 in February, driven by a Medicare Advantage Star Ratings headwind for Bonus Year 2026 that lowers quality bonus payments. Separately flagged 2027 MA plan exits affecting about 600,000 members, roughly 40% (about 240,000) typically get recaptured into other Humana plans, so the genuinely contestable pool is closer to 360,000.

“Our No. 1 priority is to make the necessary progress to remain on track to deliver on our 2028 commitment of returning to a sustainable margin of at least 3%.”

Celeste Mellet, CFO, Humana

Watch: Whether GAAP EPS guidance is cut a third time, and the October Star Ratings release, the direct driver of this quarter's cut.

Consolidated MCR 92.2%

A genuine 8.6% EPS beat, largely offset in market reaction by a 450 bps Marketplace MCR guidance deterioration, cutting full-year Marketplace guidance to a $0.75 per share loss. For 2027, Molina flagged premium revenue of about $46.5 billion, down from the $48 billion Investor Day target, mainly on planned Marketplace reduction and California's shift of undocumented members from managed Medicaid to fee-for-service, plus a planned exit from its Medicare Advantage prescription drug (MAPD) product.

“We're seeing high cost drug utilization without corresponding HCC to drive risk adjustment, which is creating an imbalance.”

Joe Zubretsky, President and CEO, Molina Healthcare

Watch: Whether Marketplace guidance holds at a $0.75 loss, or slips further, and how the MAPD exit lands in 2027 guidance.

Adjusted MBR 86.3%, +40 bps YoY, flat year over year excluding the sweep

Surpassed the high end of its own guidance across key metrics and raised full-year guidance, though revenue came in modestly below consensus. The MBR improvement is entirely the CMS new-member risk-adjustment sweep, excluding it, Alignment was flat year over year. Also flagged a lower share of EBITDA landing in H2 versus a year ago, driven by new incremental investment, enough to send shares down despite the beat.

“We expect approximately 30% of our full year adjusted EBITDA to be generated in the second half, compared to approximately 40% a year prior.”

James Head, CFO, Alignment Healthcare

Watch: Whether the H2 investment step-up holds EBITDA guidance, spanning Care Anywhere clinical operations, earlier hiring, automation, AI, and 2027 market-launch prep, potentially another double-digit millions of spend across H2.